The role of Rb in determining de novo resistance to CDK4/6 inhibitors has already been implicated in BC.15–19 Here we aimed to investigate if CCNE1 and the combined analysis of CCNE1 and RB1 as CCNE1/RB1 ratio could also represent a marker of de novo resistance to palbociclib. Here, CDK4 is linked to breast cancer.